Two weeks and $20 billion after a major failure in Alzheimer’s disease, Biogen (BIIB) isn’t quite ready to bail on a controversial approach to treating the disorder.

Dr. Michael Ehlers, Biogen’s head of research, said Monday that the company is “looking very closely” at the data on aducanumab, an Alzheimer’s drug meant to slow the disease by targeting sticky brain plaques called beta-amyloid. Last month, Biogen terminated two large studies of aducanumab after determining that the drug had no hope of succeeding. Now Biogen must decide what that failure means for the rest of its work in Alzheimer’s, a ruling Ehlers said will arrive “in the coming weeks.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy